Mainolfi Nello's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Aug 5, 2021
- Accession no.
- 0001209191-21-049922
- Filed
- Aug 5, 2021
- Trade date
- Aug 3-4, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $402.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mainolfi NelloCIK 0001821189 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2021 | Common Stock | MOption exerciseAcquired | +5,669 | $2.08 | +$11,791.52 | 457,868 | Direct | |
| Aug 3, 2021 | Common Stock | SSaleDisposed | −5,669 | $60.07F2 | −$340,536.83 | 452,199 | Direct | |
| Aug 4, 2021 | Common Stock | MOption exerciseAcquired | +1,037 | $2.08 | +$2,156.96 | 453,236 | Direct | |
| Aug 4, 2021 | Common Stock | SSaleDisposed | −1,037 | $60.03F3 | −$62,251.11 | 452,199 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2021 | Common Stock | MOption exerciseDisposed | −5,669 | $0.00 | $0 | 77,762 | Direct | |
| Aug 4, 2021 | Common Stock | MOption exerciseDisposed | −1,037 | $0.00 | $0 | 76,725 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.